Repair Biotechnologies Announces 48% Reversal of Atherosclerotic Plaque Lipids in a Preclinical Mouse Study

BOSTON, M.A.–Repair Biotechnologies, Inc. announced today breakthrough results from a preclinical study of the Cholesterol Degrading Platform (CDP) in a mouse model of late-stage cardiovascular disease. A single treatment of the CDP drug developed by Repair Biotechnologies resulted in a 48% reversal of the obstruction of aortic blood vessels by lipid-based plaque. Additionally, Repair Biotechnologies […]

Reason to present at the 6th Aging Research for Drug Discovery Forum in Basel

Friday, June 21, 2019 – Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Reason, Co-founder and CEO of Repair Biotechnologies; Founder and writer of Fight Aging!, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel […]

Repair Biotechnologies Raises $2.15M Seed Round to Develop Drugs for Age-Related Diseases

SYRACUSE, N.Y.–Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atherosclerosis. The $2.15 million in funding was led by Jim Mellon, the billionaire investor and Chairman of Juvenescence Ltd. Also participating in the round are Emerging Longevity Ventures, […]

Repair Biotechnologies Closes Pre-Seed Round, Joins Grapeseed.bio Incubator

Repair Biotechnologies, a startup developing therapies with the goals of reversing atherosclerosis and atrophy of the thymus, is proud to announce it has raised a pre-seed round from leading institutions and angel investors in the growing longevity science community, including Methuselah Foundation, SENS Research Foundation, and others. Founded by Reason and Bill Cherman in April […]